ssential hypertension is the most common cardiovascular disease, 1, 2 with genetic elements contributing up to 30% to 50% of the blood pressure variability. 3 Identifying contributing genes may allow us to recognize vulnerable individuals, to classify patients in subgroups with definite genetic and pathogenic mechanisms and to achieve better prevention and therapeutics. Using knowledge of pathways involved in cardiovascular regulation, many genes have been implicated in the pathophysiology of hypertension by the candidate gene linkage approach. The approach relies on studies of single nucleotide polymorphic (SNP) markers, in most cases derived from experimental rodent models of the disease. Genes responsible for vasoactive peptides, their receptors, and sodium homeostasis have taken center stage because of the role of these processes in the regulation of fluid volume and vascular reactivity.
However, in spite of intense efforts (11 199 publications for "human hypertension/genetics" listed in PubMed by April 2007) the attempts to replicate association studies have not been encouraging. The question has been raised as to whether high impact journals should even publish these studies. 4 The reasons for this problem are clear. Blood pressure is controlled by a complex combination of processes with redundant balancing pressor and depressor mechanisms. Hypertension is a polygenetic condition with multiple interactions of networked genes, strongly influenced by environmental factors. Genes and the environment affect the onset, severity, progression, prognosis and treatment of the disease, and their influence differs among ethnic groups or even population subgroups. 1, 2 Our knowledge of the mechanisms of blood pressure control and the pathogenesis of hypertension is not complete. Adequate genetic analysis and phenotype definition will not be possible until such mechanisms are better understood. The effect of only one gene is likely to be small and inconsistent across different genetic and environmental backgrounds, a few alleles in a handful of genes are not likely to explain increased blood pressure, and differences among populations are anticipated rather than surprising. 5 We should not be surprised that initial findings usually fail when applied to different populations.
In a manuscript published in this issue, 6 the authors used SNP-haplotype analysis in a relatively isolated genetic population. They reported the association of the Q276L variant of the ␣-1Na ϩ ,K ϩ -ATPase (ATP1A1) 7, 8 and the S44/M74 variant of the dual endothelin-angiotensin II (ET-1-Ang II) (Dear) receptor 9,10 with hypertension and also with normal blood pressure. The authors localized and characterized the human Dear receptor by transfection into Cos1 cells, determination of binding affinities, and its immunoreactivity to an anti-human Dear antibody. They concluded that this association, together with the expression of ATP1A1 and Dear in renal tubular cells and vascular endothelium, implicate both variants in the pathogenic mechanisms of hypertension. 6 Analysis of this publication requires two major comments. The first relates to the significance of the ATP1A1 and Dear variants. Ruiz-Opazo's group previously discovered dual receptors for vasoactive peptides. 9, 11 They proposed these receptors as molecular links to explain the interaction between very important systems linked to hypertension. 10, 12 In parallel, they reported that variants of the ␣1 Na ϩ ,K ϩ -ATPase, the key enzyme implicated in the development of salt-sensitive hypertension 13, 14, 15 are also linked to the disease in the salt-sensitive/salt-resistant (DS/DR) Dahl rat model of hypertension. 7, 8, 16, 17 Based on immunological methods, the authors found that the Q276L variant protein was expressed exclusively in DS rats, and that in transgenic DS rats bearing the DR wild-type ␣1 Na ϩ ,K ϩ -ATPase there was a reduction of the salt-sensitive hypertension and renal disease. 7 This strongly implicates the variant not only in hypertension but also in salt sensitivity. 7 These discoveries were novel and of great interest, and it is surprising that such a provocative body of work has not been replicated by independent groups. Instead, the proposal that the Na ϩ ,K ϩ -ATPase variants may contribute to the pathogenesis of hypertension has been hotly disputed. 18, 19, 20, 21 A number of issues should be clarified before the validity and significance of these novel and provocative findings may be properly established. Using the DS/DR model, the authors first reported that the S44/M74 variant in DS cosegregated with high blood pressure in female Dahl rats, whereas in the DR variant (S44P/M74T) the affinity for Ang II was lost. 10 Characterization of the Dear receptor in mice 22 and humans 6 revealed loss of Ang II affinity, and the presence of affinity for the vascular endothelial growth factor signal peptide (VEGFsp). 22 The lack of conservation of the Ang II binding domain suggested that the Ang II site is not relevant for the receptor function, calling into question its current nomenclature. 22 Dear is a 14 kDa receptor with a single transmembrane domain, 9,10 structurally very different from the ET-1 (and Ang II) seven membrane domain, G protein-coupled receptors 23 (Figure) . To be considered receptors, proteins should combine the properties of ligand binding, incorporation to specific membrane sites and signal transduction. A full Dear receptor characterization, such as those performed for other receptor candidates in hypertension 24 is needed before it may be considered as a major player in hypertension and saltsensitivity. Signal transduction mechanisms for VEGFsp in the Dear receptor have not been studied, and the novel proposal that VGEFsp is a mimetic ligand for the ET-1 site must be clarified. Characterization should include establishing the relevance of the ET and VEGFsp binding sites, their association with specific signal transduction mechanisms and distribution studies using in situ hybridization to complement immunocyto-chemical findings. The use of antibodies requires stringent controls to avoid erroneous interpretation of data. 25, 26 Strict controls must be applied to the use of specific antibodies to detect of the Q276L and Q276 mutants of the ␣ subunit isoforms of Na ϩ ,K ϩ -ATPase, particularly because the antibodies in question are proposed to differentiate single amino acid substitutions. 8 The wild-type Q276 variant is present not only in normotensive DR but also in spontaneously hypertensive rats (SHR). 8 This calls into question the generalization of an association of the Q276L variant with hypertension and salt sensitivity, because the SHR are also salt sensitive. 27 Molecular determinants involved in the binding of Angiotensin II, endothelin-1, and vascular endothelial growth factor signal peptide to their respective receptors. Amino acids postulated to participate in agonist peptide binding in the rat Ang II AT 1 , 50 rat Dear, 9 mouse Dear, 22 human The Dear receptor 9 was discovered in the rat by application of Blalock's molecular recognition theory (MRT). The theory is based on hydropathic complementarity, proposing that noncoding, or complementary, strands of genomic DNA encode antisense peptides and that this is the basis for the evolution of peptide receptors. 28 Ruiz-Opazo's group used oligonucleotide probes for each ET-1 and Ang II receptors, sequentially. They independently isolated, from cDNA libraries, identical DNA clones encoding single polypeptide receptors with dual peptide binding sites. 9, 11 The MRT theory is controversial 29, 30 and was not confirmed in the case of Ang II, vasopressin and other receptors. 30, 31 Most evidence for the MRT is based on immunological techniques 30 and these methods are subject to question as mentioned above. Moreover, many putative receptors isolated according to MRT theory have not turned out to be receptors. 30 This questions the universal applicability of MRT.
The second comment relates to general problems and limitations of association studies in hypertension and other complex heterogeneous disorders, outlined in a recent editorial. 32 Glorioso and coworkers 6 studied a cohort of essential hypertensive patients, with only 196 female and 237 male hypertensives. The relatively isolated Sardinian population was selected to reduce environmental variability. The phenotype analysis was limited to blood pressure determinations, and normotensives were on average 14 years older than hypertensive subjects. The original studies on DS and DR rats described an association of Dear S44/M74 with gender. 10 Association with gender also occurs in the present study. 6 Surprisingly, gender associations are opposite; with female gender in DS rats, with male gender in humans. 6 It is difficult to explain this discrepancy. The association of the S44/M74 mutant with both hypertension and normal blood pressure 6 is confusing and requires further explanation. For these reasons, and because the size of the sample is small, it is too early to determine whether or not the polymorphisms studied in the present communication are associated with hypertension.
Association between SNPs and phenotypes does not necessarily prove functional causality of disease. None of the candidate genes identified by linkage studies using SNPs has shown strong linkage with hypertension, and the results have been conflicting, with few replications between populations. 2, 32, 33, 34 Several steps can be taken to prevent further confusion and lack of replication. It is important to use rodent models of genetic hypertension critically for translational studies between rat and human, taking advantage of developments in genome analysis. It is now possible to conduct genome-wide studies in rat models to identify quantitative trait loci (QTLs) of interest. 1, 35, 36 The use of genome-wide scans using techniques to detect microsatellite polymorphisms and multiple SNPs, and analysis of the complete human genome sequence data 37 may complement the hypothesis-driven candidate gene approach to discover novel genes that have not yet been implicated in the pathogenesis of hypertension. 38, 39 To determine candidate genes that merit translational studies in human populations, the strongest evidence is the transgenic rescue experiment, the rescue of the mutant animal from the disease phenotype following genomic incorporation of a DNA clone containing the normal allele. 40 Successful complementation provides direct functional evidence for the role of the gene in question, and there are recent successful examples of this approach. 41, 42 Because negative evidence in replication studies is expected from statistical theory, 5 high quality studies should include large sample sizes with high power statistical analyses. Insufficient numbers may prevent us from determining whether a particular SNP is associated with hypertension at all. The complete studies should include extensive phenotype 
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Dual Receptor and Na ؉ ,K ؉ -ATPase in Hypertension characterization, report associations that make biological sense, contain an initial study as well as an independent replication, and systematically investigate the interaction between genes and the environment. 43, 44 Important phenotype characteristics should be carefully defined in terms of present age, age of onset of hypertension, gender, disease severity and body size, with consideration of disease progression from the early to the later stages of the disease. Replication studies should use similar inclusion and exclusion criteria and include a population of similar extraction and ethnic background, exposed to similar environmental factors, including differences in lifestyle and protein and salt intake. 2, 5 Subjects on antihypertensive treatments should be included because familial components of blood pressure variance are important. This information is lost when treated patients are excluded, reducing the evidence of linkage. 45 Family-based analysis is more powerful than population-based studies for detecting linkage and/or linkage disequilibrium. 34, 46 However, even when isolated founder populations are studied by extensive phenotyping and whole genome-linkage scans, many loci are revealed. These loci probably interact in a nonlinear fashion, 2, 47 indicating that the genetic variations in founder populations may not be relevant to other populations.
Better study designs require a collaborative multidisciplinary approach. These study designs should include sharing and combining, before publication, the data resources and the results obtained from different but similar studies and between scientific teams 32, 48 and they should be supported by the editorial boards of high impact journals. Mondry 33 suggested that all association studies should be registered in a public access electronic database and should be supported by a decision from editorial boards not to consider inappropriately designed studies for the review process, similar to that required for clinical trials. 49 A similar process should be applied to grant reviews, because increased funding and further molecular and statistical sophistication may not be sufficient and may very well be adding to the confusion. We need more stringent requirements to guide future studies in the right direction, eliminating any positive publication bias and the tendency to over-interpret marginal results. Recognition of the complexity of hypertension and the difficulties ahead, improved study design, data sharing and collaborative studies, coupled with stringent criteria for acceptance in high impact journals, will permit us to advance our understanding of a disease of such immense importance for clinical practice and public health.
